stockportfolio.pro
Stocks / DOCS vs TXG
DOCS vs TXG
Doximity, Inc. and 10x Genomics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Doximity, Inc. (DOCS) | 10x Genomics, Inc. (TXG) | |
|---|---|---|
| Market cap | $3.7B | $3.7B |
| Revenue (latest FY) | $644.86M | $642.82M |
| Net income (latest FY) | $196.05M | $-43.54M |
| Revenue growth (5y CAGR) | 25.5% | 16.6% |
| Net margin | 30.4% | -6.8% |
| Return on equity | 20.6% | -5.5% |
| P/E ratio | 20.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DOCS — free Open TXG — freeFrequently asked questions
Which is bigger, DOCS or TXG?
10x Genomics, Inc. is larger by market capitalization — $3.7B versus $3.7B.
Which grows faster, DOCS or TXG?
Over the last five fiscal years, Doximity, Inc. grew revenue faster — 25.5%/yr versus 16.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.